Physician profile
Barry S Horowitz
NPI 1437163003
$627,743.01
in general payments reported to CMS, 2019-2025
72 companies · $60K in 2025
The $60K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $72K · 2021: $95K · 2022: $94K · 2023: $89K · 2024: $64K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $184K · Consulting Fee: $13K · Food and Beverage: $10K · Travel and Lodging: $5,152 · Education: $29.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $184,165.25 |
| Consulting Fee | $13,315.00 |
| Food and Beverage | $10,131.51 |
| Travel and Lodging | $5,151.76 |
| Education | $29.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $422,992.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $107,457.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $36,076.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $15,952.96 | 2019-2020 | |
| Abbvie INC. | $12,118.86 | 2019-2025 | |
| Esperion Therapeutics, INC. | $6,928.34 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $4,909.25 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $3,185.73 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $2,452.45 | 2019-2025 | Freestyle Libre 3 |
| Vivus LLC | $2,212.71 | 2019-2024 | Qsymia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,588.41 | 2019 | |
| Amgen INC. | $1,242.61 | 2019-2025 | Evenity, Repatha, Tepezza |
| Eli Lilly and Company | $1,109.86 | 2019-2024 | |
| Tosoh Bioscience, INC. | $1,078.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,024.82 | 2021-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $852.03 | 2019-2025 | Afrezza |
| Insulet Corporation | $724.62 | 2022-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $603.62 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $572.16 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $470.84 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $436.46 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $339.22 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Antares Pharma, INC. | $317.07 | 2019-2025 | Xyosted |
| Radius Health, INC. | $263.50 | 2019-2025 | Tymlos |
| Sequel Med Tech, LLC | $246.05 | 2025 | Twiist |
| Medtronic, INC. | $223.68 | 2021-2024 | Minimed 780g |
| Neurocrine Biosciences, INC. | $215.65 | 2024-2025 | |
| Horizon Therapeutics Plc | $209.84 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $200.72 | 2019-2025 | Unithroid |
| Amarin Pharma, INC. | $186.82 | 2019-2021 | |
| Beta Bionics, INC. | $145.58 | 2024 | Ilet Bionic Pancreas |
| Ipsen Biopharmaceuticals, INC | $143.81 | 2019 | |
| Madrigal Pharmaceuticals | $123.10 | 2025 | Rezdiffra |
| Corcept Therapeutics | $116.62 | 2023-2025 | Korlym |
| Lifescan, INC. | $111.33 | 2019-2022 | |
| Alvogen INC | $62.08 | 2022-2025 | Teriparatide |
| Sanofi Pasteur INC. | $59.05 | 2019-2023 | |
| Medtronic Minimed, INC. | $56.47 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $53.08 | 2021-2025 | Isturisa, Signifor Lar |
| Halozyme INC | $49.17 | 2023 | |
| Ascendis Pharma Endocrinology INC | $42.66 | 2023-2025 | Yorvipath |
| Vanda Pharmaceuticals INC. | $41.28 | 2019-2020 | |
| Nevro Corp. | $40.29 | 2022-2023 | Senza |
| Pfizer INC. | $39.90 | 2023-2024 | |
| Verity Pharmaceuticals INC. | $37.21 | 2024 | Tlando |
| Shire North American Group INC | $36.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.98 | 2020-2021 | |
| Globus Medical, INC. | $33.00 | 2025 | Senza |
| Quidel Corporation | $32.32 | 2019 | |
| Cequr Corporation | $32.07 | 2021-2024 | Cequr Simplicity |
| Regeneron Healthcare Solutions, INC. | $31.42 | 2023 | Praluent, Evkeeza |
| Acerus Pharmaceuticals Corporation | $27.11 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $24.97 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.11 | 2024 | Crysvita |
| Astellas Pharma US INC | $21.62 | 2025 | Veozah |
| Averitas Pharma INC. | $21.09 | 2024 | Qutenza |
| Kyowa Kirin, INC. | $17.26 | 2024 | Crysvita |
| Alnylam Pharmaceuticals INC. | $17.05 | 2020 | |
| Vistapharm, INC. | $14.99 | 2021 | |
| Amryt Pharma Holdings LTD | $13.96 | 2022 | |
| Tolmar, INC. | $13.37 | 2023 | |
| Companion Medical, INC. | $13.28 | 2020 | |
| Cardiovascular Systems INC. | $11.96 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $10.84 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$29,594.88 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.